Triple test

Last updated
Triple test
Synonyms Triple screen,Bart's test
Test ofchromosomal abnormalities

The triple test, also called triple screen, the Kettering test or the Bart's test, is an investigation performed during pregnancy in the second trimester to classify a patient as either high-risk or low-risk for chromosomal abnormalities (and neural tube defects).

Contents

The term "multiple-marker screening test" is sometimes used instead. [1] [2] This term can encompass the "double test" and "quadruple test" (described below).

The Triple screen measures serum levels of AFP, estriol, and beta-hCG, with a 70% sensitivity and 5% false-positive rate. It is complemented in some regions of the United States, as the Quad screen (adding inhibin A to the panel, resulting in an 81% sensitivity and 5% false-positive rate for detecting Down syndrome when taken at 15–18 weeks of gestational age) [3] and other prenatal diagnosis techniques, although it remains widely used in Canada [4] and other countries. A positive screen indicates an increased risk of chromosomal abnormalities (and neural tube defects), and such patients are then referred for more sensitive and specific procedures to receive a definitive diagnosis, often prenatal diagnosis via amniocentesis, although the stronger screening option of cell-free fetal DNA screening (also popularly known as noninvasive prenatal screening) is frequently offered. The Triple test can be understood as an early predecessor to a long line of subsequent technological improvements. In some American states, such as Missouri, Medicaid reimburses only for the Triple test and not other potentially more accurate screening tests, whereas California offers Quad tests to all pregnant women. [5]

While the triple test can be performed at any point between 15 and 21.9 weeks of gestation, the highest detection rate for open neural defects is given by a test performed between 16 and 18 weeks of gestation. [6]

Conditions screened

The most common abnormality the test can screen is trisomy 21 (Down syndrome). In addition to Down syndrome, the triple and quadruple screens assess risk for fetal trisomy 18 also known as Edwards syndrome, open neural tube defects, and may also detect an increased risk of Turner syndrome, triploidy, trisomy 16 mosaicism, fetal death, Smith–Lemli–Opitz syndrome, and steroid sulfatase deficiency. [7]

Values measured

The triple test measures the following three levels in the maternal serum: [8]

  1. alpha-fetoprotein (AFP)
  2. human chorionic gonadotropin (hCG)
  3. unconjugated estriol (UE3)

Interpretation

The levels may indicate increased risk for certain conditions or may be benign:

AFP UE3 hCG Associated conditions
lowlowhigh Down syndrome
lowlowlow trisomy 18 (Edward's syndrome)
highn/an/a neural tube defects (like spina bifida that may have associated increased levels of acetylcholinesterase in the amnionic fluid), omphalocele, gastroschisis, multiple gestation (like twins or triplets), or an underestimation of gestational age.

An estimated risk is calculated and adjusted for the expectant mother's age; [9] if she is diabetic; if she is having twins or other multiples, and the gestational age of the fetus. Weight and ethnicity may also be used in adjustments. [10] Many of these factors affect the levels of the substances being measured and the interpretation of the results: [10]

An example of an algorithm for indications for further testing depending on the outcome of non-genetic blood tests including the triple test. Prenatal Down syndrome screening algorithm.png
An example of an algorithm for indications for further testing depending on the outcome of non-genetic blood tests including the triple test.

The test is for screening, not for diagnosis, [12] and does not have nearly the same predictive power as that of genetic blood testing (testing cell-free fetal DNA, or invasive genetic testing which are performed by amniocentesis or chorionic villus sampling. The screening test carries a much lower risk to the fetus than invasive testing, however, and in conjunction with the age-related risk of the patient it is useful to help determine the need for more invasive tests.

Variations

If only two of the hormones above are tested for, then the test is called a double test. A quad test tests an additional hormone, inhibin. Furthermore, the triple test may be combined with an ultrasound measurement of nuchal translucency. [ citation needed ]

Double test

Free beta hCG and PAPP-A are measured. However, the maternal age, weight, ethnicity etc. are still included. In the UK the double test is part of the combined test for prenatal diagnostics. [13]

Quadruple test

A test of levels of dimeric inhibin A (DIA) is sometimes added to the other three tests, under the name "quadruple test." [14] Other names used include "quad test", "quad screen", or "tetra screen." Inhibin A will be found high in cases of trisomy 21 and unchanged in cases of trisomy 18. [15]

Inhibin AAssociated conditions
High Trisomy 21 (Down syndrome)
Unchanged Trisomy 18 (Edwards syndrome)
Variable Trisomy 13 (Patau syndrome)

See also

Related Research Articles

Obstetrics is the field of study concentrated on pregnancy, childbirth and the postpartum period. As a medical specialty, obstetrics is combined with gynecology under the discipline known as obstetrics and gynecology (OB/GYN), which is a surgical field.

<span class="mw-page-title-main">Amniocentesis</span> Sampling of amniotic fluid done mainly to detect fetal chromosomal abnormalities

Amniocentesis is a medical procedure used primarily in the prenatal diagnosis of genetic conditions. It has other uses such as in the assessment of infection and fetal lung maturity. Prenatal diagnostic testing, which includes amniocentesis, is necessary to conclusively diagnose the majority of genetic disorders, with amniocentesis being the gold-standard procedure after 15 weeks' gestation.

<span class="mw-page-title-main">Alpha-fetoprotein</span> Fetal analogue of serum albumin

Alpha-fetoprotein is a protein that in humans is encoded by the AFP gene. The AFP gene is located on the q arm of chromosome 4 (4q13.3). Maternal AFP serum level is used to screen for Down syndrome, neural tube defects, and other chromosomal abnormalities.

<span class="mw-page-title-main">Obstetric ultrasonography</span> Use of medical ultrasonography in pregnancy

Obstetric ultrasonography, or prenatal ultrasound, is the use of medical ultrasonography in pregnancy, in which sound waves are used to create real-time visual images of the developing embryo or fetus in the uterus (womb). The procedure is a standard part of prenatal care in many countries, as it can provide a variety of information about the health of the mother, the timing and progress of the pregnancy, and the health and development of the embryo or fetus.

<span class="mw-page-title-main">Prenatal testing</span> Testing for diseases or conditions in a fetus

Prenatal testing is a tool that can be used to detect some birth defects at various stages prior to birth. Prenatal testing consists of prenatal screening and prenatal diagnosis, which are aspects of prenatal care that focus on detecting problems with the pregnancy as early as possible. These may be anatomic and physiologic problems with the health of the zygote, embryo, or fetus, either before gestation even starts or as early in gestation as practicable. Screening can detect problems such as neural tube defects, chromosome abnormalities, and gene mutations that would lead to genetic disorders and birth defects, such as spina bifida, cleft palate, Down syndrome, trisomy 18, Tay–Sachs disease, sickle cell anemia, thalassemia, cystic fibrosis, muscular dystrophy, and fragile X syndrome. Some tests are designed to discover problems which primarily affect the health of the mother, such as PAPP-A to detect pre-eclampsia or glucose tolerance tests to diagnose gestational diabetes. Screening can also detect anatomical defects such as hydrocephalus, anencephaly, heart defects, and amniotic band syndrome.

<span class="mw-page-title-main">Chorionic villus sampling</span> Type of prenatal diagnosis done to determine chromosomal or genetic disorders in the fetus

Chorionic villus sampling (CVS), sometimes called "chorionic villous sampling", is a form of prenatal diagnosis done to determine chromosomal or genetic disorders in the fetus. It entails sampling of the chorionic villus and testing it for chromosomal abnormalities, usually with FISH or PCR. CVS usually takes place at 10–12 weeks' gestation, earlier than amniocentesis or percutaneous umbilical cord blood sampling. It is the preferred technique before 15 weeks.

<span class="mw-page-title-main">Choroid plexus cyst</span> Medical condition

Choroid plexus cysts (CPCs) are cysts that occur within choroid plexus of the brain. They are the most common type of intraventricular cyst, occurring in 1% of all pregnancies.

<span class="mw-page-title-main">Neural tube defect</span> Group of birth defects of the brain or spinal cord

Neural tube defects (NTDs) are a group of birth defects in which an opening in the spine or cranium remains from early in human development. In the third week of pregnancy called gastrulation, specialized cells on the dorsal side of the embryo begin to change shape and form the neural tube. When the neural tube does not close completely, an NTD develops.

The Pallister–Killian syndrome (PKS), also termed tetrasomy 12p mosaicism or the Pallister mosaic aneuploidy syndrome, is an extremely rare and severe genetic disorder. PKS is due to the presence of an extra and abnormal chromosome termed a small supernumerary marker chromosome (sSMC). sSMCs contain copies of genetic material from parts of virtually any other chromosome and, depending on the genetic material they carry, can cause various genetic disorders and neoplasms. The sSMC in PKS consists of multiple copies of the short arm of chromosome 12. Consequently, the multiple copies of the genetic material in the sSMC plus the two copies of this genetic material in the two normal chromosome 12's are overexpressed and thereby cause the syndrome. Due to a form of genetic mosaicism, however, individuals with PKS differ in the tissue distributions of their sSMC and therefore show different syndrome-related birth defects and disease severities. For example, individuals with the sSMC in their heart tissue are likely to have cardiac structural abnormalities while those without this sSMC localization have a structurally normal heart.

<span class="mw-page-title-main">Nuchal scan</span> Routine ultrasound done between 11 and 14 weeks pregnancy

A nuchal scan or nuchal translucency (NT) scan/procedure is a sonographic prenatal screening scan (ultrasound) to detect chromosomal abnormalities in a fetus, though altered extracellular matrix composition and limited lymphatic drainage can also be detected.

<span class="mw-page-title-main">Triploid syndrome</span> Chromosomal disorder in which there are three copies of every chromosome

Triploid syndrome, also called triploidy, is a chromosomal disorder in which a fetus has three copies of every chromosome instead of the normal two. If this occurs in only some cells, it is called mosaic triploidy and is less severe.

The genetics and abortion issue is an extension of the abortion debate and the disability rights movement. Since the advent of forms of prenatal diagnosis, such as amniocentesis and ultrasound, it has become possible to detect the presence of congenital disorders in the fetus before birth. Specifically, disability-selective abortion is the abortion of fetuses that are found to have non-fatal mental or physical defects detected through prenatal testing. Many prenatal tests are now considered routine, such as testing for Down syndrome. Women who are discovered to be carrying fetuses with disabilities are often faced with the decision of whether to abort or to prepare to parent a child with disabilities.

<span class="mw-page-title-main">Trisomy 16</span> Partial or complete triplication of chromosome 16

Trisomy 16 is a chromosomal abnormality in which there are 3 copies of chromosome 16 rather than two. It is the most common trisomy leading to miscarriage and the second most common chromosomal cause of it, closely following X-chromosome monosomy. About 6% of miscarriages have trisomy 16. Those mostly occur between 8 and 15 weeks after the last menstrual period.

<span class="mw-page-title-main">Velamentous cord insertion</span> Velamentous placenta

Velamentous cord insertion is a complication of pregnancy where the umbilical cord is inserted in the fetal membranes. It is a major cause of antepartum hemorrhage that leads to loss of fetal blood and associated with high perinatal mortality. In normal pregnancies, the umbilical cord inserts into the middle of the placental mass and is completely encased by the amniotic sac. The vessels are hence normally protected by Wharton's jelly, which prevents rupture during pregnancy and labor. In velamentous cord insertion, the vessels of the umbilical cord are improperly inserted in the chorioamniotic membrane, and hence the vessels traverse between the amnion and the chorion towards the placenta. Without Wharton's jelly protecting the vessels, the exposed vessels are susceptible to compression and rupture.

Elevated alpha-fetoprotein refers to a state where alpha-fetoprotein levels are outside of the reference range.

Ravinder (Rav) Dhallan is the chairman and chief executive officer of Ravgen.

Cell-free fetal DNA (cffDNA) is fetal DNA that circulates freely in the maternal blood. Maternal blood is sampled by venipuncture. Analysis of cffDNA is a method of non-invasive prenatal diagnosis frequently ordered for pregnant women of advanced maternal age. Two hours after delivery, cffDNA is no longer detectable in maternal blood.

The anomaly scan, also sometimes called the anatomy scan, 20-week ultrasound, or level 2 ultrasound, evaluates anatomic structures of the fetus, placenta, and maternal pelvic organs. This scan is an important and common component of routine prenatal care. The function of the ultrasound is to measure the fetus so that growth abnormalities can be recognized quickly later in pregnancy, to assess for congenital malformations and multiple pregnancies, and to plan method of delivery.

<span class="mw-page-title-main">Pregnancy Outcome Prediction study</span>

The Pregnancy Outcome Prediction (POP) Study is a prospective cohort study of 4,512 women who have never given birth, recruited at the Rosie Hospital between January 2008 and July 2012.

Noninvasive prenatal testing (NIPT) is a method used to determine the risk for the fetus being born with certain chromosomal abnormalities, such as trisomy 21, trisomy 18 and trisomy 13. This testing analyzes small DNA fragments that circulate in the blood of a pregnant woman. Unlike most DNA found in the nucleus of a cell, these fragments are not found within the cells, instead they are free-floating, and so are called cell free fetal DNA (cffDNA). These fragments usually contain less than 200 DNA building blocks and arise when cells die, and their contents, including DNA, are released into the bloodstream. cffDNA derives from placental cells and is usually identical to fetal DNA. Analysis of cffDNA from placenta provides the opportunity for early detection of certain chromosomal abnormalities without harming the fetus.

References

  1. Renier MA, Vereecken A, Van Herck E, Straetmans D, Ramaekers P, Buytaert P (March 1998). "Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down's syndrome". Hum. Reprod. 13 (3): 744–8. doi: 10.1093/humrep/13.3.744 . PMID   9572446.
  2. Yudin MH, Prosen TL, Landers DV (October 2003). "Multiple-marker screening in human immunodeficiency virus-positive pregnant women: Screen positivity rates with the triple and quad screens". Am. J. Obstet. Gynecol. 189 (4): 973–6. doi:10.1067/S0002-9378(03)01053-6. PMID   14586337.
  3. Lao M, Calhoun BC, Bracero LA, Wang Y, Seybold DJ, Broce M, Hatjis CG (2009). "The ability of the quadruple test to predict adverse perinatal outcomes in a high-risk obstetric population". J Med Screen. 16 (2): 55–59. doi:10.1258/jms.2009.009017. PMID   19564516. S2CID   23214929.
  4. sogc.org Archived 2009-06-28 at the Wayback Machine
  5. cdph.ca.gov Archived 2017-02-12 at the Wayback Machine
  6. "Understanding the Triple Test". Sonora Quest Laboratories. Retrieved 1 February 2023.
  7. Benn PA (2002). "Advances in prenatal screening for Down syndrome: I. general principles and second trimester testing". Clin. Chim. Acta. 323 (1–2): 1–16. doi:10.1016/S0009-8981(02)00186-9. PMID   12135803.
  8. Ball RH, Caughey AB, Malone FD, et al. (2007). "First- and second-trimester evaluation of risk for Down syndrome". Obstet Gynecol. 110 (1): 10–7. doi:10.1097/01.AOG.0000263470.89007.e3. PMID   17601890. S2CID   10885982.
  9. "Downs Syndrome Screening at Nottingham City Hospital". Archived from the original on 2008-06-12. Retrieved 2007-12-20.
  10. 1 2 Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd ed. Chapter 25
  11. Diagram by Mikael Häggström, using following source: Jacquelyn V Halliday, Geralyn M Messerlian, Glenn E Palomaki. "Patient education: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)". UpToDate. This topic last updated: Feb 16, 2023.
  12. Lamlertkittikul S, Chandeying V (2007). "Experience on triple markers serum screening for Down syndrome fetus in Hat Yai, Regional Hospital". J Med Assoc Thai. 90 (10): 1970–6. PMID   18041410.
  13. "Antenatal care for uncomplicated pregnancies". National Institute for Health and Care Excellende. 26 March 2008. Retrieved 10 October 2016.
  14. Wald NJ, Morris JK, Ibison J, Wu T, George LM (2006). "Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers". Prenat. Diagn. 26 (6): 559–64. doi:10.1002/pd.1459. PMID   16700087. S2CID   1751873.
  15. Spencer K, Liao AW, Ong CY, Flack NJ, Nicolaides KH (2001). "Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks". Prenat Diagn. 21 (7): 571–574. doi:10.1002/pd.125. PMID   11494294. S2CID   32154357.